Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$44.24 USD

44.24
2,648,035

-0.88 (-1.95%)

Updated May 28, 2024 04:00 PM ET

After-Market: $44.24 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

    Mark Vickery headshot

    Strong Q4 Earnings Ahead of the Bell: TWX, GSK, ALK

    A slew of new Q4 earnings reports hit the tape this morning, covering a wide range of industries from pharma to airlines to media.

      Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y

      Glaxo reported core earnings of 48 cents per American depositary share, missing our consensus estimate of 57 cents.

        Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.

        Amgen Inc. (AMGN) announced that the FDA has approved Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

          GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1

          GW Pharmaceuticals plc (GWPH) reported first-quarter fiscal 2017 loss of 77 cents per share, much narrower than both the Zacks Consensus Estimate of a loss of $1.35 and the year-ago figure of 82 cents.

            Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

            How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?

              Merck???s Keytruda Gets Priority Review for Bladder Cancer

              Merck & Co., Inc.???s (MRK) two supplemental Biologics License Applications (sBLA) for its anti-PD-1 therapy, Keytruda, have been accepted under priority review by the FDA.

                GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?

                GlaxoSmithKline plc (GSK) is scheduled to report fourth-quarter 2016 and full-year results on Feb 8. Last quarter, the company delivered a positive earnings surprise of 7.79%.

                  Merck Keytruda Gets EU Approval for First-Line Lung Cancer

                  Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy Keytruda has been approved by the European Commission for the first-line treatment of adult patients with metastatic non-small cell lung cancer.

                    Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

                    Value investing is easily one of the most popular ways to find great stocks in any market environment.

                      Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

                      Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

                        Bristol-Myers, J&J Ink Immunotherapy Research Collaboration

                        Bristol-Myers (BMY) entered into an immunotherapy clinical research collaboration with Johnson & Johnson to evaluate a combination of Opdivo and Darzalex.

                          4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017

                          Pfizer's shares surpassed that of large-cap pharma industry in 2016. The stock rose 0.6% in 2016.

                            Merck (MRK) Does Well in 2016: Reasons for Outperformance

                            Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.

                              Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

                              Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

                                Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data

                                Pfizer, Inc. (PFE) announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug, Chantix.

                                  Big Pharma Face Off: Is Merck More Attractive than J&J?

                                  Johnson & Johnson (JNJ) and Merck & Co. Inc. (MRK) are some of the better-performing large-cap pharma stocks

                                    Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                                    Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

                                      The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                                      The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts

                                        Tracey Ryniec headshot

                                        Is Brexit a Buying Opportunity?

                                        Value investors should keep an eye on what is going on in Great Britain right now.

                                          Mark Vickery headshot

                                          Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others

                                          After a busy session after the bell yesterday, including strength from Apple, we see another long list of reporting companies this morning.

                                            Brian Bolan headshot

                                            CDXS and LOGI are Aggressive Growth Stocks

                                            Biotech supply chain and computer peripherals are the focus

                                              Brian Bolan headshot

                                              Bull of the Day: Codexis (CDXS)

                                              Think of this stock as the supply chain to big biotech and that is driving huge earnings growth.